Sunshine Lake Pharma jumps most on record on FDA marketing nod for insulin injection

Sunshine Lake Pharma

04/05/2026 04:24

** Shares of Sunshine Lake Pharma 6887.HK jump 11.5% to HK$45.86, set for the biggest one-day pct rise since debut in Hong Kong on August 7, 2025

** Stock hits the highest level since April 1

** China-based pharmaceutical products producer says its Insulin Glargine Injection has received marketing approval from the U.S. Food and Drug Administration (FDA)

** Insulin Glargine Injection is for treatment of adult and paediatric patients with type 1 diabetes and adult patients with type 2 diabetes for glycaemic control

** YTD, Hong Kong stock down 0.6%, while benchmark Hang Seng Index .HSI up 2.6%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))